Safety and Efficacy of a Low Dose Naloxone Infusion in NICU Patients
When narcotic pain medicine, like fentanyl or morphine, is given to adults and children for several days, they often develop a tolerance to the medicine. This means they may need higher doses over time to get the same amount of pain control. When it is time to stop the medicine, the dose has to be decreased slowly so that the patient does not have withdrawal symptoms.
Naloxone is a medicine that at high doses can reverse the effects of narcotics. At very small doses it may help prevent tolerance and lessen the severity of withdrawal symptoms. This could mean less narcotic pain medicine is needed over fewer days.
The purpose of this research study is to see if giving naloxone to neonates who require narcotic infusions is safe and effective. Safety will be measured by the incidence of side effects. Efficacy will be measured by monitoring for changes in pain and sedation scores and need for more pain medicine.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studie Locaties
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64108
- Children's Mercy Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Neonates > 36 0/7 weeks estimated gestational age
- Less than 30 days of life
- Requiring admission to to the Neonatal Intensive Care Unit
- Requiring continuous infusions of fentanyl or morphine analgesia
- Anticipated to require opioid infusions for at least four days
- Patients must be enrolled within 120 hours of initiating opioid infusions
- All patients will also require mechanical ventilation prior to study entry.
Exclusion Criteria:
- Preterm infants < 36 weeks gestation
- Neonates with major neurologic anomalies, seizures
- Opioid infusion administration for > 120 hours prior to study entry
- Patients requiring ECMO support prior to study entry
- Neonates born to mothers who are known to be opioid dependent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
The primary outcome variable will be a change in N-PASS scores. N-PASS scores will be compared before, during, and after administration of naloxone.
Tijdsspanne: Before, during, and after administration of naloxone
|
Before, during, and after administration of naloxone
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
The secondary outcome variable will be any changes in dosing of opioids within four hours of initiating or increasing naloxone infusion. Vital signs will be recorded per NICU protocol and closely monitored for changes.
Tijdsspanne: Collected and compared for the time period before, during, and for 5 days after naloxone infusion is administered
|
Collected and compared for the time period before, during, and for 5 days after naloxone infusion is administered
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Eugenia K Pallotto, MD, Children's Mercy Hospital Kansas City
Studie record data
Bestudeer belangrijke data
Studie start
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .